

PanCa Monitor

Test Report

Patient Information

Requisition Number	
Patient Name	
ID Number	
Date of Birth	
Gender	<input type="checkbox"/> M <input type="checkbox"/> F
Patient Phone Number	
Patient E-mail	
Name of Lab	
Lab Phone Number	
Name of Physician	
Date of Collection	
Date of Report	

Test Report

Name:

Date of Birth:

ID:

Patient Test Result

Current CTC Count	<input type="text" value="8"/>
Baseline Count (For Recurrence Monitoring Only)	<input type="text" value="5"/>
Current CTC Trend (Minimum 3 blood draws required after baseline to establish trend)	<input type="text" value="High"/>

Comments

Your current CTC trend is high. Consultation with a treating physician for further confirmatory workup is recommended.

Electronic Signatures

This test was developed and its performance characteristics determined by CellMax. Clinical decisions regarding care and treatment of patients should not be solely based on this test. Not all disease will be accurately detected. How this information is used to guide patient care is the responsibility of the physician.

Lab Supervisor Leon Chen _____

Date _____

Pathologist Manana Kvezereli-Javey, MD, PhD _____

Date _____

Copyright CellMax Life, 2016. All Rights Reserved

Patient Medical History

Cancer Diagnosis	Tumor Type		Date of Diagnosis
	Pathological Diagnosis		
	Tumor Stage (TNM)	Metastasis Site	Date of Most Recent Treatment


Testing History

Baseline

Test Date	CTC Counts
01/21/2017	5

CTC Counts

Test Date	CTC Counts
01/21/2017	5
04/11/2017	5
07/22/2017	7
10/17/2017	8



About The Test

The CellMax Life PanCa Monitor test is intended for the isolation and enumeration of circulating tumor cells (CTCs) from whole blood. PanCa Monitor is an in-vitro test that uses the CellMax proprietary microfluidic chip device (CMx Platform™) coated with EpCAM antibodies, epithelial cell markers (CK8/18) and tissue specific markers (e.g. PSMA, Mammaglobin) to detect CTCs in the peripheral blood. PanCa Monitor can be used to accurately detect the presence and/or monitor recurrence for 16 different types of cancers. The list of cancers include: Breast, Colorectal, Lung, Prostate, Ovarian, Endometrial, Pancreatic, Liver, Thyroid, Small Intestine, Gastric, Bladder, Skin, Head and Neck, Hepatobiliary, and Esophagus. PanCa Monitor results are reported as number of CTCs identified in the blood and/or CTC trend is reported in case of recurrence monitoring after 3 consecutive measurements. Analytical sensitivity of PanCa Monitor is 1 CTC/7.5mL blood. PanCa Monitor should be used in conjunction with other clinical methods for monitoring such as imaging, lab tests, physical examination, and a complete medical history review to assess patient prognosis through the course of treatment and/or disease.

Limitations of the test: PanCa Monitor is designed to detect circulating tumor cells (CTCs) of epithelial origin. The test utilizes tissue specific markers to identify origin of the epithelial cells derived from various tissue types. It has been demonstrated that CTC count can be affected by various types of treatment regimens including chemotherapy and radiation. Effective therapy may significantly decrease the CTC count below the limit of detection. To assess disease current status, it is recommended the test to be administered before and after the treatment course.

Indications For Ordering

The PanCa Monitor test is appropriate for patients who have been previously diagnosed with any one of the cancers listed above, and for which cancer monitoring is warranted. The test is intended to be used as an ancillary tool for monitoring a patient's cancer status during the course of disease. Serial testing should be used in conjunction with other clinical monitoring methods such as laboratory test and imaging modalities. It is recommended that a patient is "therapy free" for at least 7 days at the time of blood draw.

Interpretations of Results

Results of the first blood draw from CellMax PanCa Monitor are for physician reference and is used to establish the baseline count. Each test administered will be reported in CTC numbers. Baseline (1-2) tests need to be administered before meaningful results can be obtained. CTC trend can only be reported after minimum of 3 consecutive measurements.

Important Notice

Clinical decisions regarding care and treatment of patients should not be solely based on this test. CellMax PanCa Monitor test results should be used in conjunction with all clinical information derived from diagnostic tests (e.g. imaging or laboratory tests), physical examination, and complete patient medical history, in accordance with appropriate management procedures.

Utilization of the information provided is the sole responsibility of the treating physician. The test is not intended to replace any standard of care testing modalities, but rather to aid them for a better assessment of a patient's cancer during the disease course.

Disclaimer

This test was developed and its performance characteristics determined by CellMax Life, a clinical laboratory accredited by the College of American Pathologists (CAP) to perform testing. Clinical decisions regarding care and treatment of patients should not be solely based on this test. Not all disease will be accurately detected. How this information is used to guide patient care is the responsibility of the physician. This test is used for clinical purposes, and should not be regarded as investigational or for research. This test is not a diagnostic test and results of this test must be utilized in conjunction with other monitoring clinical tools.

The CellMax Life test is designed to assist health care practitioners in providing additional clinical information. The information therein should not be relied upon as being complete or accurate, nor should it be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. Medical knowledge develops rapidly and new evidence may emerge between the time information is developed to when it is published or read.

CellMax Life provides this information on an "as is" basis, and makes no warranty, express or implied, regarding the information. CellMax specifically disclaims any warranties of merchantability or fitness for a particular use or purpose. CellMax Life assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this information or for any errors or omissions.

The information herein is not continually updated and may not reflect the most recent evidence. The information addresses only the topics specifically identified therein and is not applicable to other interventions, diseases, or stages of diseases. This information does not mandate any particular course of medical care. Further, the information is not intended to substitute for the independent professional judgment of the treating physician, as the information does not account for individual variation among customers. CellMax Life provides this information on an "as is" basis, and makes no warranty, express or implied, regarding the information. CellMax Life specifically disclaims any warranties of merchantability or fitness for a particular use or purpose. CellMax Life assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this information or for any errors or omissions.

References

1. Hao-Wei Teng, et al. "A new classification scheme for recurrent or metastatic colon cancer after liver metastasectomy". *JCMA* 74, p.493, 2011
2. Stewart BW, Wild CP, (Ed.). *World Cancer Report 2014*. International Agency for Research on Cancer, Lyon, France, 2014.
3. Chen et al, *Int J Colorectal Dis*. 2010 May;25(5):567-71.
4. Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Wolff BG, *Surg Gynecol Obstet*. 1992 Jan; 174(1):27-32.
5. Millner et al. Circulating tumor cells: a review of present methods and the need to identify heterogeneous phenotypes. *Ann Clin Lab Sci*. 2013 Summer;43(3):295-304.
6. Nesteruk, et al. "Evaluation of Prognostic Significance of Circulating Tumor Cells Detection in Rectal Cancer Patients Treated with Preoperative Radiotherapy: Prospectively Collected Material Data." *BioMed Research International*, vol. 2014, Article ID 712827, 6 pages, 2014.
7. Shen et al, "Detection of circulating tumor cells: Clinical relevance of a novel metastatic tumor marker," *Exp. Ther. Med*; Volume 2 Issue 3; May 2011
8. Rahbari et al. "Meta-analysis Shows That Detection of Circulating Tumor Cells Indicates Poor Prognosis in Patients With Colorectal Cancer." *Gastroenterology* 2010;138:1714–1726
9. Marchetti et al. "Circulating Tumor Cells Count Predicts Survival in Colorectal Cancer Patients." *J Gastrointestin Liver Dis*, September 2014 Vol. 23 No 3: 279-284 2014
10. Cohen SJ, Punt CJ, Iannotti N, et al: Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. *J Clin Oncol* 2008 Jul;26 (19):3212-3221
11. Klein, et al. "Systemic spread is an early step in breast cancer," *Cancer Cell*. 2008 Jan;13(1):5868
12. Yang et al. Epithelial–mesenchymal plasticity in carcinoma metastasis. *Genes & Dev*. 2013. 27: 2192-2206
13. Cristofanilli M, Budd GT, Ellis MJ, et al: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. *N Engl J Med* 2004;351:781-791
14. deBono JS, Scher HI, Montgomery RB, et al: Circulating tumor cells predict survival benefit from treatment in the metastatic castration-resistant prostate cancer. *Clin Cancer Res* 2008 October 1;14(19):6302-6309
15. Budd TG, Cristofanilli M, Ellis MJ, et al: Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast Cancer. *Clin Cancer Res* 2006 12:6403-6409
16. Dawood S, Broglio K, Valero V, Reuben J, Handy B, Islam R, Jackson S, Hortobagyi GN, Fritsche H, Cristofanilli M: *Cancer*. 2008, 113: 2422-2430. 10.1002/cncr.23852
17. Wang FB, Yang XQ, Yang S et al. A higher number of circulating tumor cells in peripheral blood indicates poor prognosis in prostate cancer patients—a meta-analysis. *Asian Pac J Cancer Prev* 2011; 12(10):2629-35
18. Gazzaniga, Paola, et al. "Prognostic value of circulating tumor cells in nonmuscle invasive bladder cancer: a CellSearch analysis." *Annals of oncology* (2012): mdr619.

Simple Blood Test. Real Time Protection.



CellMax Life (USA)
1271 Oakmead Parkway
Sunnyvale, CA 94085
USA



CellMax Life (ASIA)
18F.-1, No.3, Park St.
Nangang Dist., Taipei City 11503,
Taiwan (R.O.C.)



www.cellmaxlife.com
info@cellmaxlife.com

CellMax Life, All Rights Reserved, 2017